General Assembly

Amendment

January Session, 2025

LCO No. **8785**

Offered by:
REP. RUTIGLIANO, 123rd Dist.
REP. CANDELORA V., 86th Dist.
REP. O'DEA, 125th Dist.

To: House Bill No. **7065** File No. 730 Cal. No. 465

"AN ACT CONCERNING THE DECRIMINALIZATION OF POSSESSION OF SMALL AMOUNTS OF PSILOCYBIN."

Strike everything after the enacting clause and substitute the following in lieu thereof:

"Section 1. (NEW) (*Effective October 1, 2025*) No person may possess any amount of psilocybin, except as authorized in chapter 420 of the general statutes, unless and until the federal Food and Drug Administration has reviewed and approved the use of psilocybin.

Sec. 2. (NEW) (*Effective October 1, 2025*) Until October 1, 2028, there shall be no direct to consumer advertising in this state for any drug not reviewed and approved by the federal Food and Drug Administration.

Sec. 3. (NEW) (*Effective October 1, 2025*) (a) As used in this section:

(1) "Consumer" means an individual who is physically present in this state;

(2) "Legend drug" has the same meaning as provided in section 20-571 of the general statutes;

(3) "Person" has the same meaning as provided in section 20-571 of the general statutes;

(4) "Pharmaceutical manufacturer" has the same meaning as provided in section 21a-70h of the general statutes;

(5) "Pharmaceutical marketing firm" has the same meaning as provided in section 21a-70h of the general statutes;

(6) "Pharmaceutical representative" has the same meaning as provided in section 21a-70h of the general statutes; and

(7) "Prescribing practitioner" has the same meaning as provided in section 20-571 of the general statutes.

(b) No person engaged in trade or commerce in this state shall directly advertise any legend drug to a consumer. Nothing in this subsection shall be construed to prohibit any pharmaceutical manufacturer that is registered with the Department of Consumer Protection as a pharmaceutical marketing firm under section 21a-70i of the general statutes, or any individual who is employed or compensated by such pharmaceutical marketing firm to perform the duties of a pharmaceutical representative in accordance with the provisions of said section, from promoting or providing information regarding a legend drug for human use to a prescribing practitioner.

(c) The Commissioner of Consumer Protection may adopt regulations, in accordance with the provisions of chapter 54 of the general statutes, to implement the provisions of this section.

(d) Any violation of the provisions of subsection (b) of this section shall be deemed an unfair or deceptive trade practice under subsection (a) of section 42-110b of the general statutes."

This act shall take effect as follows and shall amend the following sections:		
Section 1	*October 1, 2025*	New section
Sec. 2	*October 1, 2025*	New section
Sec. 3	*October 1, 2025*	New section